Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5/pos/1.html?cHash=2aa63e7a3c47f54d547eeaaa494e591b&sort=asc

Kurszettel

Alle Kurse

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014